Figure 2 | Scientific Reports

Figure 2

From: Abrogation of atypical neurogenesis and vascular-derived EphA4 prevents repeated mild TBI-induced learning and memory impairments

Figure 2

AraC rescues rmTBI-induced aberrant neurogenesis. (A) Experimental time line showing 7 days pre-infusion of vehicle or 2% AraC prior to rSham or rmTBI, 50 mg/kg/day BrdU injections, repeated injuries and behavior testing paradigm. (B) Quantified data showing estimated number of BrdU+ cells/mm3 by non-biased stereology in the DG at 24 dppi. A significant attenuation of increased BrdU-labeling was seen in AraC-treated rmTBI mice compared to vehicle rmTBI. (C) AraC also reduced the number of Prox1/BrdU double-positive cells compared to vehicle rmTBI. No significant differences in the estimated number of Sox2/BrdU or NeuN/BrdU positive cells were seen between groups. (F–I) Representative confocal maximum projection z-stack images of the DG immunolabeled with BrdU (red), Prox1 (green) and DAPI (blue) with inset (white boxes). Scale = 250 µm in (F–I) and 50 µm in (F–I) insets. Data are represented as mean ± SEM. One-way ANOVA with Bonferroni post-hoc. *p < 0.05, ****p < 0.000. n = 6–10 mice.

Back to article page